Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR19PK: CD19-CAR T Cell Therapy and Fludarabine PK in Pediatric/AYA Leukemia
NCT06847269Phase 2Recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- May 2025
- Primary completion
- Mar 2030
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CD19R(EQ)28zeta/EGFRt+ T cells in acute lymphoblastic leukemia (ALL), sponsored by St. Jude Children's Research Hospital. Primary endpoint: Fludarabine Pharmacokinetics. Started May 2025; status: recruiting.
02
Drugs
CD19R(EQ)28zeta/EGFRt+ T cells
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT06847269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06847269.